1. Signaling Pathways
  2. Neuronal Signaling
  3. Tau Protein

Tau Protein

Tau is well established as a microtubule-associated protein in neurons. They have roles primarily in maintaining the stability of microtubules in axons and are abundant in the neurons of the central nervous system (CNS). However, under pathological conditions, aberrant assembly of tau into insoluble aggregates is accompanied by synaptic dysfunction and neural cell death in a range of neurodegenerative disorders, collectively referred to as tauopathies.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-101184
    T807
    99.06%
    T807 a novel tau positron emission tomography (PET) tracer.
    T807
  • HY-144681
    LY3372689
    98.74%
    LY3372689 (Formulaic Ia) is an orally active O-GlcNAcase (OGA) enzyme inhibitor. LY3372689 can be used for tauopathies research, including Alzheimer’s disease.
    LY3372689
  • HY-134968
    TTBK1-IN-1
    Inhibitor 99.53%
    TTBK1-IN-1 is a potent, selective and brain-penetrant tau tubulin kinase 1 (TTBK1) inhibitor with an IC50 of 2.7 nM. TTBK1-IN-1 can be used for the research of alzheimer’s disease and related tauopathies. TTBK1-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    TTBK1-IN-1
  • HY-101183
    THK5351
    98.94%
    THK5351 can be radiolabeled and used as a radiotracer for in vivo imaging of tau pathology in the brain.
    THK5351
  • HY-P99399
    Semorinemab
    Inhibitor 99.90%
    Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease.
    Semorinemab
  • HY-132582C
    IONIS-MAPTRx sodium
    Inhibitor
    IONIS-MAPTRx sodium is the first Tau-lowering antisense oligonucleotide (ASO). IONIS-MAPTRx sodium has the potential for the research of Alzheimer Disease.
    IONIS-MAPTRx sodium
  • HY-134850
    QC-01–175
    Degrader
    QC-01-175 is a heterobifunctional molecule, which degrades aberrant tau. QC-01-175 reduces the levels of A152T and P301L mutant tau protein and protects neurons from tau-mediated toxicity and improve cell survival. (Pink: ligand for target protein Aberrant tau ligand 1 (HY-W453397); Black: linker NH2-PEG3 (HY-W007545); Blue: ligand for E3 ligase Pomalidomide (HY-10984))
    QC-01–175
  • HY-161458
    GSK-3β inhibitor 16
    Activator
    GSK-3β inhibitor 16 (compound 7c) is a GSK-3β inhibitor with the IC50 of 4.68 nM. GSK-3β inhibitor 16 decreases Tau hyperphosphorylated aggregate and alleviates cognitive impairments in the Scopolamin (HY-N0296)-induced model in mice.
    GSK-3β inhibitor 16
  • HY-156586
    ASN90
    99.63%
    ASN90 is a specific and orally active O-GlcNAcase (OGA) enzyme inhibitor with IC50 value of 10.2 nM. ASN90 can be used for the research of neurodegenerative diseases, such as tauopathies and α-synucleinopathies.
    ASN90
  • HY-P1675A
    Acetyl-PHF6 amide TFA
    Acetyl-PHF6 amide TFA (AcPHF6 TFA) is a tau derived hexapeptide.
    Acetyl-PHF6 amide TFA
  • HY-132582
    IONIS-MAPTRx
    Inhibitor
    IONIS-MAPTRx (BIIB080) is the first Tau-lowering antisense oligonucleotide (ASO). IONIS-MAPTRx has the potential for the research of Alzheimer Disease.
    IONIS-MAPTRx
  • HY-P99471
    Bepranemab
    Inhibitor 99.79%
    Bepranemab (UCB 0107) is a humanized, full-length IgG4 monoclonal antibody that binds to a central tau epitope (amino acids 235-250). Bepranemab can be used for Alzheimer’s disease (AD) research.
    Bepranemab
  • HY-138669
    C004019
    Degrader 99.37%
    C004019 is a small-molecule PROTAC. C004019 simultaneously recruites tau and E3-ligase (Vhl) and thus selectively enhances ubiquitination and proteolysis of tau proteins. C004019 can be used for Alzheimer disease (AD) research.
    C004019
  • HY-154851
    GSK-3 inhibitor 3
    Inhibitor 98.72%
    GSK-3 inhibitor 3 is a selective, orally active and brain-penetrant inhibitor of GSK-3, with IC50s of 0.35 nM and 0.25 nM for GSK-3α and GSK-3β, respectively. GSK-3 inhibitor 3 lowers levels of tau protein phosphorylation at S396 in a triple-transgenic mouse Alzheimer’s disease model, with IC50 of 10 nM. GSK-3 inhibitor 3 can be used for neurological disease research.
    GSK-3 inhibitor 3
  • HY-156585
    CNS-11
    Inhibitor 98.88%
    CNS-11 is a compoud that disaggregates tau fibrils. CNS-11 can be used for Alzheimer's disease (AD) research.
    CNS-11
  • HY-139307
    MG-2119
    99.67%
    MG-2119 is a potent monomeric tau and α-syn aggregation inhibitor. MG-2119 is a potential agent for neurological disorders research.
    MG-2119
  • HY-P99648
    Gosuranemab
    Inhibitor
    Gosuranemab (BMS-986168) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab binds to human N-terminal tau residues 15-22. Gosuranemab has the potential for the research of alzheimer’s disease (AD).
    Gosuranemab
  • HY-141660
    BSc3094
    98.68%
    BSc3094 is a Tau aggregation inhibitor. BSc3094 can be used for the research of Alzheimer's disease (AD).
    BSc3094
  • HY-P1707A
    Tau protein (592-597), human TFA
    99.20%
    Tau protein (592-597), human TFA is a peptide fragment of human Tau protein. The dysfunction of Tau protein is involved in neurodegeneration and dementia.
    Tau protein (592-597), human TFA
  • HY-19738
    NQTrp
    Inhibitor 98.15%
    NQTrp, an aromatic naphthoquinone-tryptophan hybrid molecule, an inhibitor of the aggregation of the tau protein with generic anti-amyloidogenic effects. NQTrp inhibits the in vitro aggregation of hexapeptide (41GCWMLY46 within the N-terminus of γD-crystallin) as well as full-length γD-crystallin.
    NQTrp
Cat. No. Product Name / Synonyms Application Reactivity